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Itis well known that ionizing radiation (IR) can damage DNA through a direct action, producing single- and double-strand breaks
on DNA double helix, as well as an indirect eﬀect by generating oxygen reactive species in the cells. Mammals have evolved several
and distinct DNA repair pathways in order to maintain genomic stability and avoid tumour cell transformation. This review
reports important data showing a huge interindividual variability on sensitivity to IR and in susceptibility to developing cancer;
this variability is principally represented by genetic polymorphisms, that is, DNA repair gene polymorphisms. In particular we
have focussed on single nucleotide polymorphisms (SNPs) of XRCC1,ag e n et h a te n c o d e sf o ras c a ﬀold protein involved basically
in Base Excision Repair (BER). In this paper we have reported and presented recent studies that show an inﬂuence of XRCC1
variants on DNA repair capacity and susceptibility to breast cancer.
1.Introduction
During evolution, mammalian cells have optimised distinct
pathways to repair DNA preserving genome integrity and
avoiding ﬁxing of harmful mutations. DNA lesions could be
causedbyexternalinsultsaswellasbyexposuretomutagenic
substances. They could also be produced endogenously,
for example, by reactive oxygen species generated during
physiological processes.
Five main diﬀerent repair mechanisms have been desc-
ribed in humans: MMR (Mismatch Repair), BER (Base Exci-
sion Repair), NER (Nucleotide Excision Repair), HRR (Ho-
mologous Recombination Repair), and NHEJ (Nonhomolo-
gous End Joining).
MMR is a postreplicative mechanism that ensures the
application of the Watson-Crick base pairing principle on
DNA double helix, discriminating mismatches resulting
from DNA polymerase errors, and rectifying them to avoid
mutation [1].
Generally, BER corrects DNA base lesions due to
oxidative, alkylation, deamination damages via two general
pathways: short patch and long patch [2]; NER is a more
versatile pathway that senses the distortion caused by a base
damaged by chemical (i.e., cross-linking agents) or physical
(i.e.,UV)agentsandexcisesatractoffewnucleotidesaround
the lesion [3].
In BER and NER mechanisms, single-strand breaks
(SSBs) are an enzymatic consequence of the repair of
damaged DNA but they could represent a serious risk for
cells if they are not ﬁlled by a polymerase and rejoined by
DNA ligase. In fact during DNA replication SSBs could be
converted to more lethal DNA double-strand breaks (DBSs).
DSBs could generate deletions, chromosome translocations,
hence genomic instability [4, 5] and in some circumstances
induce cell cycle arrest and apoptosis [6, 7].
Homologous Recombination Repair (HRR) and Non-
homologous DNA-End Joining (NHEJ) are the two major
pathways of DSBs repair. A third system, single-strand
annealing (SSA), shares HRR and NHEJ components. The
fundamental diﬀerence between HRR and NHEJ is the
dependence on DNA homology template [8].
All DNA repair pathways are ﬁnely regulated and many
of the genes involved in these mechanisms are highly
conserved from bacteria to humans. This high conservation
degree indicates the importance of repair pathways in living
organisms.2 Journal of Nucleic Acids
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Figure 1: Human XRCC1 protein and gene structure. (a) The diagram shows XRCC1 domains and the regions of interaction with other
components of BER. (b) The diagram shows the structure of the gene with the most common and studied single nucleotide polymorphisms
(SNPs): −77 T → C, R194W, R280H and R399Q. Each of them is detailed in the text.
In literature it has been well documented that defects
in DNA repair are associated with human disorders. Several
genetic diseases are linked to mutations in genes involved in
DNA repair, that is, XP Xeroderma Pigmentosum, CS Cock-
ayne Syndrome, FA Fanconi Anemia, and NBS Nijmegen
Breakage Syndrome. Furthermore, studies conducted on
knockout and mutant animal models have suggested the key
function of speciﬁc components of DNA repair machineries.
Despite the lack of a pathological phenotype, humans
bearing variant alleles of DNA repair genes could show a
diﬀerent individual response to DNA damage.
The principal source of interindividual variability is
represented by genetic polymorphisms. The presence of
polymorphic alleles in DNA repair genes may alter the repair
capacity modifying the biological responses to exogenous
and endogenous DNA insults, both at cellular and tissue
level,andtheindividualsusceptibilityindevelopingdiﬀerent
kind of disease, such as cancer.
InthisreviewwefocussedontheinﬂuenceofDNArepair
polymorphisms on human individual sensitivity to Ionising
Radiation (IR) treatment and susceptibility to cancer; in
particular we are interested in better understanding whether
SNPs in XRCC1 gene, encoding, for a scaﬀold protein
involved basically in BER pathway, could impair DNA repair
eﬃciency so increasing the risk to develop tumour, such as
sporadic breast cancer.
2.XRCC1 Polymorphisms andIRExposure
XRCCgenes,abbreviationofX-raycrosscomplementing,are
components of several diﬀerent damage recovery pathways,
and XRCC proteins do not show similarity in biochemical
functions.
The human XRCC1 (X-ray repair cross-complementing
group 1) gene, located on chromosome 19q13.2, encodes for
a 633aa protein (Figure 1) that plays an important role in
BER and single-strand breaks repair (SSBR), following expo-
sure to endogenous reactive oxygen species, IR or alkylating
agents [9, 10]. Additionally, XRCC1 seems to take part also
in DSBs repair [11, 12]. L´ evy et al. [11] demonstrated that
the DNA-dependent protein kinase (DNA-PK), a key factor
in NHEJ, is able to phosphorylate XRCC1 (Ser 371) after
ionizing radiation that causes XRCC1 dimer dissociation.
This posttranslation modiﬁcation seems to be important for
rejoining DSBs in response to DNA damage caused by IR, as
also showed by the failure of S371L mutant XRCC1 to rescue
DSBs repair defect in deﬁcient EM9 cells.
In 2004 Audebert et al. showed an involvement of the
XRCC1/Lig III complex in DSBs rejoining. The complex,
otherwise involved in BER, could act in an alternative end-
joining mechanism that complements DNA-PK/XRCC4/Lig
IV dependent NHEJ [12].
A lot of information about XRCC1 function has been
derived from mutant mammalian cell lines; XRCC1 mutants
were initially identiﬁed in the AA8 strain of Chinese hamster
ovary (CHO) cells, and four of these, denoted EM7, EM9,
EM-C11 and EM-C12, represent a model to study the
consequence of the lack or a reduced level of this protein
[13].
The XRCC1 is a scaﬀold protein that interacts with other
many components of BER as DNA polymerase β,A P E 1 ,
hOGG1, poly-(ADP-ribose) polymerase and DNA ligase III
in the NH2-terminal, central, and COOH-terminal regions,
respectively, as resumed in Figure 1 [14–16].
In 1998 Shen et al. [17] described three polymorphisms
of XRCC1 gene, which resulted in non-conservative amino-
acid changes at evolutionary conserved regions: C → T
substitution in codon 194 of exon 6 (Arg to Trp); G → A
substitution in codon 280 of exon 9 (Arg to His) and G → A
substitution in codon 399 of exon 10 (Arg to Gln). (Figure 1)
Recently, Hao et al. [18] identiﬁed, in Chinese popu-
lation, another variant in the XRCC1 gene located in theJournal of Nucleic Acids 3
5 UTR (5 -untraslated region), −77 T → C. (Figure 1).
Afterwards this polymorphism was also conﬁrmed to be
present, with a higher frequency, in Caucasian population
[19, 20].
All these single nucleotide polymorphisms (SNPs) could
alter the XRCC1 function and impair DNA repair eﬃciency
or accuracy. In 1983, Setlow [21] claimed that healthy
subjects diﬀer in their intrinsic capacity in repairing DNA
damage and this variation could be a result of variants
in DNA repair genes that consequently can modify the
individual susceptibility to radiation exposure.
A report by Lunn et al. [22] suggested that XRCC1
codon 399 polymorphism located within the BRCT domain
[23] which interacts with PARP, may result in deﬁcient
DNA repair. More recently, Taylor et al. (2002) showed
that although BRCT1 domain is critical for eﬃcient single-
strand break repair and cell survival, 399 polymorphism
located within this domain did not appear to signiﬁcantly
aﬀect XRCC1 function. On the contrary, by using molecular
dynamics techniques Monaco et al. (2007) predicted the
structure of wild-type and polymorphic form of BRCT1
domain of XRCC1 demonstrating that the polymorphism in
exon 10 changed the XRCC1’s secondary structure. These
contrasting results call for further investigations to clarify
whethertheArg→Glnsubstitutionincodon399couldaﬀect
DNA repair capability [24, 25].
Hu and co-workers (2001) evaluated whether amino acid
substitution variants of DNA repair genes, that is, XRCC1-
399, contribute to ionizing radiation (IR) susceptibility as
measured by prolonged cell cycle G2 delay. In γ-irradiated
lymphocytes from disease-free controls, they found a higher
mitotic delay in subjects with Arg/Gln and Gln/Gln geno-
types than homozygous wild-type ones. The diﬀerence,
however, was not statistically signiﬁcant. In conclusion, they
indicated that the XRCC1 Arg/Gln genotype may inﬂuence
cellular response to IR, particularly in women with positive
family history (FH) of breast cancer [26].
In order to elucidate the inﬂuence of the most common
SNP of XRCC1 (Arg399Gln) on the individual DNA repair
capacity, Cornetta et al. [27] assessed the repair capacity
through alkaline Comet assay in human peripheral blood
c e l l so fh e a l t h ys u b j e c t st r e a t e din vitro with X rays.
They observed that subjects with XRCC1 variant Gln/Gln
genotype exhibited lower values of DNA damage than those
with homozygous wild-type (Arg/Arg) and heterozygous
(Arg/Gln) genotypes, both at basal level and after treatment.
On the contrary, the baseline DNA damage, measured as Tail
Moment, was found to be increased in healthy individuals
bearing the XRCC1 399Gln variant allele in Weng and
colleagues’ work [28].
Hence, Cornetta et al. [27] concluded that individuals
bearing Gln/Gln genotype had fewer DNA breaks and
resolved open breaks faster than homozygote wt and het-
erozygote subjects. Anyway, as they noticed, the Comet assay
does not provide information about the ﬁdelity of DNA
repair and misrepaired lesions could lead to chromosomal-
type damage. Angelini et al. [29] demonstrated that subject
exposed to IR (both X- and γ-rays) with XRCC1 variant
genotypes had a higher frequency of micronuclei (MN) with
respect to wild type ones. Furthermore, a high chromosomal
damagecouldtriggeroﬀapoptosisincellswith399polymor-
phicgenotypesconsequentlyresultingprotectivethroughthe
elimination of potentially transformed cells. This hypothesis
is supported by Seedhouse et al. [30] who showed a
protective eﬀect of XRCC1-399 variant allele against the
development of therapy-related acute myeloblastic leukemia
(t-AML).
On the contrary, Aka et al., [31] showed that XRCC1-399
polymorphism resulted in higher residual DNA values, mea-
sured by Comet assay, after γ-ray treatment and Godderis
et al., [32] in collusion with Rzeszowska-Wolny et al. [33],
performing Comet assay and MN analysis, concluded that
XRCC1-399 did not seem to inﬂuence DNA damage repair
after γ-rays exposure.
The individual susceptibility to IR can also diﬀer in
subjects aﬀected by cancer, as interindividual variation in
therapeutic exposure to ionising radiation response revealed.
Moreover, cancer patients seem to be more radiosensitive
than healthy persons: Scott et al. [34] found that about
40% of breast cancer (BC) patients are radiosensitive in
comparison to about 9% of healthy controls.
Recently, our group analysed the response to IR exposure
in sporadic BC patients and healthy controls by measuring
DNA damage through alkaline Comet assay [35]. We did
not observe a great interindividual variation in either group
but we found that BC patients were more radiosensitive and
exhibitedasigniﬁcantlyhighermeanofbasalandIR-induced
DNA damage when compared to healthy controls. Anyhow,
in this study the impairment of BC repair capacity did not
result to be associated with XRCC1-399 polymorphism. But,
interestingly the reduced repair ability in BC patients was
related to high degrees of tissue side eﬀects.
This is in agreement with results reported by Alapetite
and colleagues who observed that BC patients with most
severe complications showed impaired rejoining as analysed
through alkaline Comet assay [36].
3.XRCC1 Polymorphisms and Risk of
Developing Cancer
RelatedtoanimpairedDNArepaircapacityandanincreased
mutagenesis, polymorphisms in DNA repair genes could
also modify the risk of developing cancer. Epidemiological
studies were focussed on assessing a possible link between
genetic factors, in particular low penetrance genes as well
as SNPs, and increased/decreased risk of tumour. Along this
line Breast Cancer (BC) is a very interesting ﬁeld of research.
It is the most common cause of cancer death in women
worldwide. Most etiologic factors are established [37–39],
but concerning the association between DNA repair SNPs
and the sporadic form of this tumour, literature data are
often contradictory.
Recently, in 2009, Huang et al. [40]p e r f o r m e dam e t a -
analysis that collected data about the association between
breast cancer and the XRCC1 polymorphisms Arg194Trp
(9411cases and 9783 controls), Arg399Gln (22481 cases and
23905 controls) and Arg280His (6062 cases and 5864
controls) in diﬀerent inheritance models [dominant model:4 Journal of Nucleic Acids
Table 1: Reported studies about the association of XRCC1-399 polymorphism and DNA repair capacity.
XRCC1-399
GENOTYPE
IR
EXPOSURE
E F F E C T SO ND N A
REPAIR CAPACITY REFERENCES
Variant γ-rays Higher mitotic delay
index
Hu et al., 2001
[26]
Variant X-and γ-rays Higher MN frequency Angelini et al.,
2005 [29]
Variant γ-rays
No-one on DNA
damage values
(Comet) Higher
background
frequency of MN
Rzeszowska et
al., 2005 [33]
Variant γ-rays Higher residual
damage (Comet)
Aka et al., 2006
[31]
Gln399Gln X-rays Lower DNA damage
(Comet)
Cornetta et al.,
2006 [27]
Variant γ-rays
No-one on DNA
damage values
(Comet) and MNCB
Godderis et al.,
2006 [32]
Variant No Higher basal DNA
damage (Comet)
Weng et al.,
2009 [28]
Variant= Arg399Gln + Gln399Gln.
Table 2: Reported studies about the association of XRCC1-399 and
BC risk.
Protective eﬀectBreast Cancer Association Consortium, 2006 [41]
Saadat et al., 2008 [42]
Risk factor
Duel et al., 2001 [43]
Moullan et al., 2003 [44]
Smith et al., 2003 [39]
Zhang et al., 2006 [45]
Huang et al., 2009 [40]
Sterpone et al., 2010 [20]
homozygouswild-typeversus(homozygousmutant+hetero-
zygous) and recessive model: (homozygous wild-type+hete-
rozygous) versus homozygous mutant).
Reference to SNPs in codon 194 and 280, they did not
appear to be risk factors for breast cancer but case-control
studies on Arg399Gln have provided conﬂicting results.
AboutXRCC1Arg399Glnpolymorphism,in2006,Breast
Cancer Association Consortium [41] reported that there was
no evidence of an association of BC with this SNP and
with a large meta-analysis Saadat et al. [42] concluded that
this polymorphism was associated with BC risk in studies
from Asian countries but not from Western countries, when
using a recessive model. On the other hand, Huang [40]
suggested that both under recessive and dominant models,
the Arg399Gln was associated with a trend of increased
breast cancer risk, regardless of ethnic subgroups division.
In agreement with this conclusion and several other studies
[39, 43–45], our group showed a slightly increase of BC risk
inCaucasiansusingdominantmodel:womenbearingatleast
one XRCC1-399 variant allele seem to be at higher risk of
developing this tumour [20].
Additionally, we found that the presence of variant
allele at codon 399 combined with the variant allele in the
promoter, −77C which alone was not associated with BC,
determined a signiﬁcantly higher risk of developing this
cancer: this combination could aﬀect strand breaks repair
as a consequence of the reduced availability of XRCC1
transcript, even in the variant form.
To date, only one other study reported the analysis of
haplotypes considering the promoter SNP together with 194,
280 and 399 polymorphisms in BC patients and healthy
controls. In collusion with our analysis [20], Brem et al. did
not ﬁnd any association between BC and promoter polymor-
phism; BC risk was positively associated with −77, 194, and
399 wild-type alleles and 280 variant allele haplotype, even if
the P value was not signiﬁcant [19].
The haplotype risk association could be an interesting
and more complete approach than association studies in
which only individual XRCC1 SNPs are considered, thus
leading to errors in risk estimation.
4. Conclusions
In this review we have focussed on the eﬀect of genetic basis
on interindividual diﬀerences in response to DNA damaging
agents.InparticularwehaveconsideredDNAdamagecaused
by ionizing radiation, commonly used in the care of tumour.
The consequences of IR exposure could be very serious
and radiation injury may develop months to years later after
treatment with numerous and individual manifestations.
Hence, radiation-induced DNA damage and its repair play
a critical role for the susceptibility of patients aﬀected by
cancer to side eﬀects after radiotherapy.
In conclusion, as the reported studies want to support
(see Table 1 and Table 2), it is an important goal of biologicalJournal of Nucleic Acids 5
and clinical research to detect genetic components like
DNA repair gene polymorphisms as possible indicators of
radiosensitivity in order to adjust radiotherapy protocols for
both sensitive and resistant patients.
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